AnaptysBio prices public offering of 2.75M shares at $36.50 for ~$100M gross

ANAPTYSBIO, INC

Gross proceeds ~$100M from sale of 2,750,498 shares at $36.50 per share.
Net proceeds to fund general corporate purposes including Phase III readiness of ANB032 and rosnilimab.
Offering expected to close on August 15, 2024, subject to customary conditions.

item 1.01 item 9.01

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001193125-24-200684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.